Global Leaders in RNA-based Therapeutics

As global leaders in the field of RNA-based therapeutics, we are aggressively leveraging our differentiated and proprietary RNA-based platforms to discover and advance innovative therapeutic candidates. read more >

Global Leaders in RNA-based Therapeutics
Novel Programs for Important Medical Needs

We are committed to the discovery and development of novel RNA-based therapeutics with the potential to provide patients transformative treatment options. Our programs target rare diseases and infectious diseases. read more >

Novel Programs for Important Medical Needs
Versatile RNA-based Therapeutics Platform

Our novel RNA-based platforms are highly differentiated, offering an opportunity to target a range of diseases and disorders via utilization of proprietary advanced chemistries and distinct mechanisms of action. read more >

Versatile RNA-based Therapeutics Platform
Kepler

Lead Program: Duchenne Muscular Dystrophy

AVI’s exon skipping therapy exhibits first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient after systemic delivery. read more >

Learn About Our Corporate Presentations Sign Up For Email Alerts